Amjevita is supplied as a 40mg/0.8mL single-dose prefilled SureClick autoinjector, and as 20mg/0.4mL and 40mg/0.8mL single-dose prefilled syringes.
Amjevita is supplied as a 40mg/0.8mL single-dose prefilled SureClick autoinjector, and as 20mg/0.4mL and 40mg/0.8mL single-dose prefilled syringes.
Follow-up colonoscopy rates were 43.3% within 90 days, 56.1% within 360 days of positive stool-based screening test result
Prevalence of advanced neoplasms 40 to 50% lower among those who underwent repeated screening ≥10 years after a negative colonoscopy
The approval was based on data from the phase 2 MOUNTAINEER trial, which included patients with HER2-positive unresectable or metastatic colorectal cancer.
The IMbrave050 study included 662 patients with HCC at high risk for recurrence after surgical resection or ablation with curative intent.
84.9 percent of 73 patients achieved objective response, including 23.3 percent with complete response
The table provided is a review of notable updates that occurred in December 2022 for investigational products in development.
Etrasimod is an oral selective sphingosine 1-phosphate (S1P) receptor modulator currently being investigated to treat a range of immuno-inflammatory diseases.
The approval for Idacio was based on a review of data that showed similar pharmacokinetics, efficacy, safety, and immunogenicity to the reference adalimumab product.